Department of Surgery, University of Toronto, Toronto, ON, Canada.
Department of Surgery, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
J Surg Oncol. 2021 Jan;123(1):12-23. doi: 10.1002/jso.26246. Epub 2020 Oct 6.
The coronavirus disease-2019 (COVID-19) pandemic is deeply impacting the accessibility of cancer patients to surgery. In resource-limited conditions, the standard of care might not be deliverable, but evidence to support alternative management strategies often exists. By revisiting available treatment options, this review provides surgical oncologists with an evidence-based framework for treating patients with gastrointestinal stromal tumor, extremity/truncal soft tissue sarcoma, and retroperitoneal sarcoma to rapidly adapt their decision-making to the constant evolution of the COVID-19 pandemic.
2019 年冠状病毒病（COVID-19）大流行深刻影响了癌症患者接受手术的机会。在资源有限的情况下，可能无法提供标准治疗，但通常存在支持替代管理策略的证据。通过重新审视现有的治疗选择，本综述为外科肿瘤学家提供了一个治疗胃肠道间质瘤、肢体/躯干软组织肉瘤和腹膜后肉瘤患者的循证框架，以便他们能够迅速根据 COVID-19 大流行的不断演变调整决策。
